Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Gapwaves publishes Annual report for 2022

Gapwaves AB has published the Annual Report for 2022. The full report is available at Gapwaves website; Financial reports, download  and as attachment to this press release.Strong position within the automotive radar market Through agreements and partnerships with Veoneer, Hella and Bosch among others, Gapwaves now is an established brand with a strong position as a globally leading supplier of waveguide antennas in the market for advanced driver assistance and automated vehicles of various types. Gapwaves has a

Sedentary time may significantly enlarge adolescents’ heart

In adolescents, sedentary time may increase heart size three times more than moderate-to-vigorous physical activity, a paper published in the Scandinavian Journal of Medicine & Science in Sports concludes. The study was conducted in collaboration between the University of Bristol in the UK, the University of Exeter in the UK, and the University of Eastern Finland. The researchers explored the associations of sedentary time, light physical activity, and moderate-to-vigorous physical activity with cardiac structure and function.Recent World Health Organization reports and guidelines note that

BioStock: Vinnova leads the work with a new innovation cluster

The government wants to see increased investments in life science and advanced therapies in Sweden and has commissioned Vinnova to establish a national innovation cluster. BioStock spoke to the  head of Vinnova’s health department, Lars Hammarström, who tells us about the assignment.Read the full article about Vinnova's mission at  biostock.se : https://www.biostock.se/en/2023/04/vinnova-leads-the-work-with-a-new-innovation-cluster/ This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/

Change in Terveystalo's Executive Team: Henri Mäenalanen appointed Chief Operating Officer, Siina Saksi leaves the company

Terveystalo Plc, Stock Exchange Release 12 April 2023 at 9:50 a.m. EEST Henri Mäenalanen, M.Sc. (engineering), born in 1983, is appointed as the Chief Operating Officer of Terveystalo Healthcare Services as of 12 April 2023 as Siina Saksi moves to a new position outside the company. Mäenalanen has worked in Terveystalo in several key roles since 2016, most recently as the Director of Operations, responsible for resource and network management. Before this, he held several management positions in the retail industry. - For almost ten years, Siina Saksi has led the core of our business,

Apotek Hjärtat’s physical stores initiate sales of Peptonics VagiVital® AktivGel

Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical stores in Sweden, starting in May.VagiVital® AktivGel is a treatment for vaginal atrophy and was the first product that Peptonic launched in intimate care. Peptonic intends to be a leading player in clinically proven intimate self-care, and there is a clear trend that people want to take greater responsibility for their own health with clinically proven self-care products.  "The need for and interest in VagiVital®

HYON AS – Notice to the Ordinary General Meeting in HYON

(Oslo, 12 April 2023) (HYON, OSE: HYON) The Ordinary General Meeting in HYON AS will take place on 19 April 2023 at 10:00 am (CEST) at the premises of the Company at Strømsø Torg 4 on 2th Floor in Drammen, Norway. Shareholders are requested to avail themselves of the possibilities of voting by proxy, as described in the notice of the meeting, and as far as possible to refrain from attending in person. Shareholders may submit their votes electronically in advance. Please see the instructions in the enclosed Notice. The Notice and the corresponding attachments will be available on

First day for trading in BoMill’s shares without the right to participate in the share issue

The first day of trading in BoMill’s shares excluding the right to obtain subscription rights is today, 12 April 2023.At the Extraordinary General Meeting on April 6, 2023, it was resolved to issue new shares with preferential rights for shareholders in BoMill of approximately a maximum of SEK 21.9 million. The Company has entered into agreements (1) inter alia with some of the shareholders, personnel, and board members regarding undertaking to subscribe by using their subscription rights, and (2) with certain shareholders concerning guarantee commitments to subscribe such shares that

HC Andersen Capital Events 12.04: Meet the top management in GomSpace

HC Andersen Capital is hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.GomSpace - Rights IssueGomSpace has announced that through a rights issue with preferential rights for the Company’s existing shareholders, it will raise up to SEK 122m, of which SEK 53.6m is guaranteed through the conversion of loans into share capital. The issuance is carried out to secure long-term financing for ongoing transitions toward a more standardized product offering.    On 12 April at 1.00PM, we will conduct an event with the

KONE publishes January-March 2023 Interim Report on Wednesday, April 26, 2023 at 12:30 p.m. EEST

KONE Corporation, press release, April 12, 2023 at 9.30 a.m. EEST KONE publishes January-March 2023 Interim Report on Wednesday, April 26, 2023 at 12:30 p.m. EEST Interim ReportKONE Corporation will publish its Interim Report for the January 1-March 31, 2023 accounting period on Wednesday, April 26, 2023 at 12:30 p.m. EEST. The report will be available on www.kone.com after publishing. Press and analyst eventsA Microsoft Teams call for the press, conducted in English, will be held on Wednesday, April 26, 2023 at 2:15 p.m. EEST. Journalists are kindly asked to sign up to media@

Market Need in the US and Europe is Estimated at 200,000 Artificial Hearts per Year - Equivalent to SEK 200 Billion - And the Trend is Accelerating

Press Release 12 April, 2023 Industry players and Realheart estimate that the market potential for total artificial hearts (TAHs) is over 200,000 units per year in Europe and the US. Realheart believes it is well positioned to take significant market share with its four-chamber artificial heart."Sales will likely only be limited by the number of artificial hearts we have the capacity to produce," said the company's CEO Ina Laura Perkins. "We have great advantages with our TAH because we have started to automate parts of the production process at an early stage of development. Having said

Exclusive small batch from Mackmyra – only 3017 bottles

“Mackmyra Muddus" is a limited small batch with exclusive content, as well as an exclusive appearance. The flavor profile comes from casks that previously carried wild raspberry wine and cloudberry wine. The whisky, which is only available in 3017 bottles, has a character typical of Mackmyra but is unique in its kind.Mackmyra Muddus is the first release in the new small batch concept. The whisky is handcrafted with extra love and has a new look that speaks of luxury and elegance. Quite simply, it is an exclusive piece of Swedish whisky history for the collector and connoisseur of life who

Invitation to presentation of Pandox’s interim report January–March 2023

Pandox AB (publ) publishes its interim report for the period January–March 2023 on 26 April 2023, at 07:00 CEST, followed by a webcasted telephone conference at 08:30 CEST.   Afterwards, a proprietary presentation on the international hotel market, separate from Pandox’s earnings presentation, will be held by Robin Rossmann, Managing Director, STR International.   To follow the conference by phone, please use one of the following numbers: SE: +46 8 505 163 86 UK: +44 20 319 84884 US: +1 412 317 6300 Pin code: 4762730#   To follow the presentation via webcast,

Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification

Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the approved certification are important milestones for achieving CE marking for pHyph, the company’s antibiotic-free treatment for bacterial vaginosis. *ISO 13485 is the medical device industry’s most widely used international standard for quality management.Anna-Karin holds a master’s degree from Mälardalen University majoring on Quality in the Life Science Industry, following a degree in

GARO's Annual Report for 2022

GARO´s Annual Report 2022 has today been published at the company’s website.GARO AB (publ) today announces that the company’s Annual Report 2022 is now published and available at the corporate website www.garogroup.se . The financial year covers the period from January 1 to December 31, 2022. For more information, please contact:Helena Claesson, CFO +46 (0)70 676 07 50 This information is such information that GARO aktiebolag is obligated to publish in accordance with the Swedish Securities Market Act. The information was

Readly welcomes 71 French regional newspapers to its platform

Readly , the European market leader in digital magazines and newspapers has added 71 regional daily, weekly and bi-weekly newspapers to its growing French content portfolio. The platform continues to broaden its newspaper offering across markets, which now includes some of the most popular newspapers across its core European markets. With these new signings, Readly is continuing to meet the needs of its French subscribers by providing them with international, national and local news in line with their requests.Readly launched its platform in France in November

The Norwegian FSA advises SR-Bank as SIFI

The Financial Supervisory Authority of Norway advises the Ministry of Finance to name SpareBank 1 SR-Bank ASA as a Systemically Important Financial Institution with an additional capital requirement of 100 basis points. Link to the message from the Norwegian FSA (Norwegian only): https://www.finanstilsynet.no/nyhetsarkiv/nyheter/2023/rad-om-systemviktige-foretak/  Contacts:  Morten Forgaard, investor relations, +47 916 21 425  Dag Hjelle, Head of Treasury, +47 909 50 088

Top five life science stocks in Q1

Life science investors were cautious entering 2023. Only a few funding rounds were fully subscribed and several were cancelled waiting for better times. The broad market performed better, at least until the first major crisis in the wake of the rapid interest rate hikes. BioStock listed the best performing Nordic life science stocks in Q1.Read the full article at biostock.se : https://www.biostock.se/en/2023/04/top-five-life-science-stocks-in-q1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Adapteo launches Solar Power as a Service

Today, Adapteo premier launches an easy-to-use, add-on solar power service. This is the result of Adapteo’s commitment to making solar energy accessible for temporary buildings. It enables Adapteo’s customers – such as schools, care centres, and offices – to immediately decrease the carbon footprint related to energy consumed and enjoy the benefits of producing renewable energy. With the launch of Solar Power as a Service, Adapteo also introduces Adapteo Essentials – a new product portfolio including optional add-on solutions and services available for all Adapteo customers. Adapteo, a

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022

April 12, 2023 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2022. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.The Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to info@indexpharma.com, or by mail to InDex Pharmaceuticals Holding AB (publ), Berzelius väg 13, 171 65 Solna, Sweden. For more information:Jenny Sundqvist, CEOPhone: +46 8 122 038 50E-mail: jenny.sundqvist@indexpharma.com Johan Giléus,

Correction of Year-End Report during ongoing revision

Correction of Year-End Report during ongoing revision. The net profit for the full year 2022 is adjusted upwards by 1586 KSEK.During the ongoing revision of the Annual Report for 2022, MindArk has identified a deviation from the Year-End-Report for 2022, which was published on February 28, 2023. The net profit for the full year 2022 will be adjusted upwards by 1586 KSEK. Thus, the following corrections arise: • The net profit for the Group for 2022 amounts to 9141 KSEK (instead of 7555 KSEK according to the Year-End-Report).The reason for the adjustment is that MindArk has identified

Metso Outotec to publish its Interim Report for January-March 2023 on Wednesday, May 3, 2023

Metso Outotec Corporation’s press release on April 12, 2023, at 09:00 a.m. EESTMetso Outotec’s Interim Report for January-March 2023 will be published on Wednesday, May 3, 2023, at about 9:00 a.m. EEST and can be found on the Metso Outotec website .  President and CEO Pekka Vauramo and CFO Eeva Sipilä will present the results in an audiocast and a conference call for analysts and investors on the same day at 12:30 p.m. EEST.  The audiocast can be followedat the company’s website 

Oriola Corporation to publish its Interim Report for January–March 2023 on 27 April 2023

Oriola Corporation  Investor news  12 April 2023 at 9:00 a.m. EEST Oriola Corporation to publish its Interim Report for January–March 2023 on 27 April 2023 Oriola Corporation will publish its Interim Report for January–March 2023 on Thursday 27 April 2023 at around 8:30 a.m. EEST. The Interim Report will be available on Oriola’s website after the publication. Welcome to join our results presentation CEO Katarina Gabrielson and CFO Timo Leinonen will present the Q1 Interim Report at a webcast meeting on the same day starting at 10.00 a.m. EEST. The link to the webcast will be

Inify Laboratories - Annual Report 2022

Stockholm – April 12, 2023 – Inify Laboratories, a company providing fully digitalized laboratory services within prostate cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2022. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be distributed upon request sent to e-mail: ir@inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com   ###     About Inify

There are no items matching the current filter
There are no more items matching the current filter
Back to top